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Background: The lectin-like domain of TNF-α can be mimicked by synthetic TIP peptides and represents an innovative
pharmacologic option to treat edematous respiratory failure. TIP inhalation was shown to reduce pulmonary edema
and improve gas exchange. In addition to its edema resolution effect, TIP peptides may exert some anti-inflammatory
properties. The present study therefore investigates the influence of the inhaled TIP peptide AP318 on intrapulmonary
inflammatory response in a porcine model of systemic sepsis.
Methods: In a randomized-blinded setting lung injury was induced in 18 pigs by lipopolysaccharide-infusion and a
second hit with a short period of ventilator-induced lung stress, followed by a six-hour observation period. The animals
received either two inhalations with the peptide (AP318, 2×1 mg kg−1) or vehicle. Post-mortem pulmonary expression
of inflammatory and mechanotransduction markers were determined by real-time polymerase chain reaction (IL-1β,
IL-6, TNF-α, COX-2, iNOS, amphiregulin, and tenascin-c). Furthermore, regional histopathological lung injury, edema
formation and systemic inflammation were quantified.
Results: Despite similar systemic response to lipopolysaccharide infusion in both groups, pulmonary inflammation
(IL-6, TNF-α, COX-2, tenascin-c) was significantly mitigated by AP318. Furthermore, a Western blot analysis shows
a significantly lower of COX-2 protein level. The present sepsis model caused minor lung edema formation and
moderate gas exchange impairment. Six hours after onset pathologic scoring showed no improvement, while gas
exchange parameters and pulmonary edema formation were similar in the two groups.
Conclusion: In summary, AP318 significantly attenuated intrapulmonary inflammatory response even without the
presence or resolution of severe pulmonary edema in a porcine model of systemic sepsis-associated lung injury.
These findings suggest an anti-inflammatory mechanism of the lectin-like domain beyond mere edema reabsorption in
endotoxemic lung injury in vivo.
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Sepsis is a frequent cause of acute respiratory distress
syndrome (ARDS). Sepsis-induced ARDS can be caused
by a primary pulmonary focus or a systemic transmis-
sion, while isolated ARDS may also trigger a systemic re-
sponse leading to multiple organ failure [1,2]. A key
mediator of early pulmonary inflammation is tumor-* Correspondence: hartmane@uni-mainz.de
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unless otherwise stated.necrosis-factor-alpha (TNF-α), which is known to exert
pleiotropic effects [3,4]. The lectin-like domain of TNF-
α, which is located at the tip of the pyramidal molecule,
elicits edema resolution and endothelial barrier sealing
effects independently from the pro-inflammatory main
effects of the cytokine. The lectin-like domain therefore
contributes to the dichotomal role of TNF-α in severe
inflammatory conditions [4]. This domain can be mim-
icked by synthetic TIP peptides, which recently emerged
as a novel approach for treatment of ARDS and are cur-
rently tested for clinical application [4-6]. Via activationral. This is an Open Access article distributed under the terms of the Creative
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cells TIP peptides help to create an osmotic gradient
leading to resolution of alveolar edema [7-9]. Edema for-
mation through microvascular hyperpermeability can
also be limited by the TIP peptide [8,10]. Furthermore,
inhalative application was shown to limit inflammatory
response in terms of leucocyte infiltration and reactive
oxygen species generation [11]. In a recent porcine
model of bronchoalveolar lavage induced ARDS inhal-
ation of the TIP peptide AP301 (APEPTICO, Vienna,
Austria) was effective in improving the overall pulmon-
ary function, which was associated with edema reduction
[12]. These findings have not been confirmed in vivo
under conditions of systemic sepsis or severe inflamma-
tory response. Based on previous in vitro data the syn-
thetic peptide AP318 may represent a more potent
variant of the initially synthesized TIP peptide [13,14],
but only showed comparable effects to the first TIP pep-
tide AP301 in a porcine model in vivo [15]. To further
characterize the effects of the lectin-like domain on
intrapulmonary inflammation, a porcine model of lipo-
polysaccharide (LPS)-induced sepsis with an additional
ventilator-induced lung injury (VILI) component was ex-
amined. Our primary hypothesis was that repetitive
AP318 inhalation would lead to an attenuation of intra-
pulmonary inflammatory response, and secondary im-
prove gas exchange and overall lung injury.
Methods
This study was approved by the state and institutional ani-
mal care committee (Landesuntersuchungsamt Rheinland-
Pfalz, Koblenz, Germany; approval number 23 177-07/
G12-1-058), and conducted in accordance with institu-
tional guidelines of the Johannes Gutenberg-University
Mainz, Germany. 18 juvenile pigs (weight 25–27 kg)
were examined in a randomized, investigator-blinded
setting.
Anesthesia and instrumentation
After sedation with intramuscular injection of ketamine
(8 mg kg−1) and midazolam (0.2 mg kg−1) and vascular
access by ear vein puncture, anesthesia was induced and
maintained by intravenous propofol and fentanyl admin-
istration (8–12 mg kg−1 h−1 / 0.1-0.2 mg h−1). A single
dose of atracurium (0.5 mg kg−1) was applied to facilitate
orotracheal intubation. Ventilation (Respirator: AVEA®,
CareFusion, USA) was started in pressure-controlled
mode with a tidal volume of (Vt) of 8 mL kg
−1, positive
end-expiratory pressure (PEEP) of 5 cmH2O, fraction of
inspired oxygen (FiO2) of 0.4 and a variable respiratory
rate to maintain normocapnia. A balanced saline solu-
tion (Sterofundin iso, B. Braun, Germany) was continu-
ously infused at a rate of 10 mL kg−1 h−1. Vascular
catheters were placed ultrasound-guided in Seldinger’stechnique and under sterile conditions: an arterial line, a
pulse contour cardiac output catheter (PiCCO, Pulsion
Medical Systems, Germany) and central venous line
were inserted via femoral access. An introducer for
a pulmonary artery catheter was placed via the right
internal jugular vein. Ventilatory and extended hemody-
namic parameters were recorded continuously (Datex S/5,
GE Healthcare, Germany). Body temperature was mea-
sured by a rectal probe and normothermia was maintained
by body surface warming.
Experimental protocol
Following instrumentation baseline parameters were
assessed at healthy state. Figure 1 summarizes the ex-
perimental protocol: systemic inflammation was induced
by continuous LPS infusion (Escherichia coli serotype
O111:B4, Sigma-Aldrich, Switzerland) for one hour at
100 μg kg−1 h−1, followed by 10 μg kg−1 h−1 for the en-
tire experiment. Initial high-dose infusion was combined
with a non-protective ventilation setting (Vt 25 mL kg
−1,
zero PEEP, FiO2 1.0) to add a VILI component. After-
wards the ventilation mode was switched to a more lung
protective setting: Vt of 8 mL kg
−1, PEEP 5 cmH2O,
FiO2 of 0.4, and a variable respiratory rate to maintain a
pH > 7.2. The animals were monitored over six hours
after sepsis induction. During the induction phase a
non-participant randomized the animals into two groups
and prepared the peptide solution for blinded endo-
tracheal inhalation:
(1) AP318 group (1 mg kg−1 AP318 at zero and three
hours, n = 9)
(2) Control group (CTRL; vehicle solution at zero and
three hours, n = 9)
The cognate TIP variant AP318 was provided by
APEPTICO (Vienna, Austria) and delivered as lyophili-
sate at – 20°C. For preparation and conduction of the
inhalation by means of a clinical nebulizer (Aeroneb
ProX, Aerogen Ltd, Ireland) a previously established,
standardized protocol was applied [15]. To maintain
hemodynamic stability (mean arterial pressure > 60 mmHg)
additional fluid boli were administered (150 ml of bal-
anced saline or hydroxyethyl starch once every hour).
Persisting instability was treated by continuous central
venous noradrenaline infusion. At the end of the experi-
ments the animals were killed in deep general anesthesia
by intravenous injection of propofol (200 mg) and potas-
sium chloride (40 mval).
Gene expression analysis and immunoblotting
To determine intrapulmonary inflammation mRNA levels
of pro-inflammatory cytokines interleukin-1β (IL-1β),
interleukin-6 (IL-6), TNF-α, and enzymes prostaglandin
Figure 1 Experimental protocol.
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synthase (iNOS) were quantified. Amphiregulin and
tenascin-c expression levels were examined as surro-
gates of mechanical stress and remodeling. Addition-
ally, ENaC expression was analyzed by quantification of
the channel’s β-subunit. Four representative samples
from the left lung (upper/lower lobe, each dependent/
non-dependent) were collected, snap frozen in liquid
nitrogen and stored at −80°C. RNA extraction and
quantification procedure by real-time polymerase chain
reaction (Lightcycler 480 PCR System, Roche Applied
Science, Germany) was conducted as previously de-
scribed in detail [16-18]. mRNA expression data were
normalized against peptidylprolyl isomerase A (PPIA)
as control gene. The applied primer sequences are
summarized in Table 1. To determine tissue protein
content of COX-2, the homogenates were analyzed by
Western blotting following standard protocols [19].
Lung tissue samples (~100 mg) were homogenized in
4 ml solubilization buffer [100 mM Tris–HCl, pH 7.4,
20% sucrose, 0.5% SDS, 1× protease inhibitor cocktail
(P2714 from Sigma-Aldrich, USA)] at 4°C using an
Ultra-Turrax dispersing device (IKA, Germany). Protein
content in the obtained homogenates was determined
by bicinchoninic acid protein assay (Pierce, USA). The
employed polyclonal, rabbit anti-cyclooxygenase-2 anti-
body (1:200; ab15191 from Abcam, UK) detected a sin-
gle, predominant band of ~70 kDa in these porcine
samples. COX-2 signal intensity was normalized for
Ponceau S staining intensity of the applied total protein
between ~25 kDa and ~170 kDa. Densitometric quanti-
fication was achieved using the commercial image ana-
lysis software AIDA (Raytest, Germany).
Hematological parameters
Blood gas values were obtained using a Rapidlab 248
device (Bayer Healthcare, Germany). Hematological
parameters were determined during baseline, at the endof sepsis/VILI induction, and after three and six hours.
Lactate plasma levels, leucocyte and platelet counts were
analyzed by the Institute of Laboratory Medicine, Med-
ical Center of the Johannes Gutenberg-University. The
plasma levels of IL-6 and TNF-α were determined by
quantifying enzyme linked immunosorbent assays (Por-
cine IL-6 Quantikine ELISA, Porcine TNF-a Quantikine
ELISA, R&D Systems, Germany) according to the manu-
facturer’s instructions.
Histopathological and lung water content assessment
The lungs were removed en-bloc after thoracotomy and
a macroscopic lung injury score [15] was applied: four
ventral and dorsal segments (each upper/lower right,
upper/lower left) of the lung surface were examined
for hemorrhage and congestion (2 points > 50%, 1 point
for < 50%, 0 points for no or minimal changes). The left
lung was weighted immediately after removal and dried
afterwards at 60°C for 72 hours to determine the dry
weight and wet to dry ratio. From the right lung samples
of the bronchoalveolar lavage fluid were taken and snap
frozen in liquid nitrogen to determine the alveolar pro-
tein content and cytokine levels by ELISA. The right
lung was then fixed in 10% buffered formalin. Represen-
tative tissue samples were paraffin embedded and cut
for hematoxylin-eosin staining. A blinded investigator
under supervision of a senior pathologist performed the
histopathological assessment. In different lung regions
(non-dependent periphery and bronchial, dependent
periphery and bronchial) morphological changes were
rated for seven criteria (alveolar edema, interstitial
edema, hemorrhage, inflammatory infiltration, epithelial
damage, microatelectasis and overdistension). The sever-
ity of each parameter ranged from 0 (no occurrence) to
5 points (complete field). For every lung region we used
the mean value of four non-overlapping fields of view.
The sum of the regional scores in all lung regions adds to
a maximum injury score of 140 points (7 parameters × 5
Table 1 Specific real-time PCR primers
PCR
assay Oligonucleotide sequence (5′-3′) GenBank no.
IL-1β S: ACCCTgCAgCTggAggAT NM_214055
A: CCTTTggAgTTTCCCAggA





















AREG S: ATTATGCTGCTGGACTGGAC NM_214376
A: TCGCTACCAGAAGGCATTT
TNC S: GAGACCTGACTGCTACAGAG NM_214230
A: CACAACGACTTCCTTGAGTG






sENACg S: ACTTCACCCCCATCTTCCAC XM_003357614
A: TTCAGGCCAAACTCAGCTC
S: sense primer, A: anti-sense primer, FL: fluorescein, CY5: CY5-labelled.
IL-1β, Sus scrofa interleukin 1 beta (IL1B), mRNA; IL-6, Sus scrofa interleukin 6
(interferon, beta 2) (IL6), mRNA; TNF-α, Sus scrofa tumor necrosis factor (TNF
superfamily, member 2) (TNF), mRNA; iNOS, Sus scrofa nitric oxide synthase 2,
inducible (NOS2), mRNA. COX-2, Sus scrofa prostaglandin G/H synthase-2
(PGHS-2), mRNA; AREG, Sus scrofa amphiregulin (AREG), mRNA; TNC, Sus scrofa
tenascin C (TNC), mRNA; PPIA, Sus scrofa peptidylprolyl isomerase A (cyclophilin
A) (PPIA), mRNA; sENACg, Sus scrofa sodium channel, non-voltage-gated 1, beta
subunit (SCNN1B), transcript variant X1, mRNA.
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Additionally, we assessed the regional distribution of each
parameter by comparison of the dependent versus non-
dependent lung regions. Similar scoring procedures were
described previously [20,21].Statistical analysis
Data are expressed as mean ± standard deviation (SD) or
box-plots. For intergroup comparisons of the primary pa-
rameters (pulmonary mRNA expression, Figures 2 and 3)
the Mann–Whitney-U-Test was used. Intragroup time
courses of repetitively measured parameters were analyzed
by Friedman ANOVA on ranks and post-hoc SNK-Test.
Differences of secondary parameters (Figures 4, 5 and 6)
between the two groups were assessed by the Mann–
Whitney-U-Test. If multiple testing was performed, P
values were adjusted by the Bonferroni method. P values
below 0.05 were regarded as significant. Comparisons of
physiological data for each time point (Table 1) were ana-
lyzed in an explorative manner by one-way ANOVA. The
statistical software SigmaPlot 12.5 (Systat Inc., USA) was
used.Results
Pulmonary and systemic inflammatory markers
Intrapulmonary mRNA quantification yielded signifi-
cantly lower overall expression of COX-2, TNF-α and
IL-6 following AP318 inhalation, while the differences in
IL-1β and iNOS expressions failed to reach significance
(Figures 2 and 3). Additionally, a Western blot shows a
significantly decreased COX-2 protein level in the lung
tissue (Figure 3). ENaC expression was comparable in
both groups (AP318 17.5 ± 9.2, CTRL 13.6 ± 7.4 [mRNA
copies]; P = 0.12). Furthermore a decreased tenascin-c
expression was detected after AP318 inhalation. No rele-
vant locoregional variations were present. IL-6 and
TNF-α levels from the bronchoalveolar lavage fluid were
not different. Secondary, the systemic inflammatory re-
sponse did not differ between the two groups. LPS infu-
sion led to a sustained and persisting leucopenia. This
was accompanied by decreases in platelet count and ris-
ing lactate levels. Plasma levels of IL-6 and TNF-α in-
creased significantly in both groups with a peak within
three hours (Figure 4).Physiological data
Table 2 summarizes the time charts of hemodynamic
and respiratory parameters. After sepsis/VILI induction
the quotient of arterial partial pressure of oxygen and
FiO2 (PaO2/FiO2) did not decrease. Afterwards PaO2/
FiO2 and dynamic lung compliance (Cdyn) significantly
decreased within three hours in both groups and per-
sisted without recovery (Figure 5). The two groups
showed no significant differences. Hemodynamic param-
eters were stable during baseline and sepsis/VILI induc-
tion, while over six hours continuous noradrenaline
infusion was required in similar dosages (Table 1; AP318
8/9 animals, CTRL 7/9 animals). Hydroxyethyl starch
was applied in all animals in comparable dosages.
Figure 2 Pulmonary expression of inflammatory cytokines and enzymes. Intrapulmonary mRNA expression [mRNA copies] of inflammatory
cytokines normalized to peptidylprolyl isomerase A (PPIA): IL-1β, IL-6, TNF-α, and iNOS. Significant intergroup differences indicated by P values.
Figure 3 COX-2 and mechanotransduction. Intrapulmonary mRNA expression [mRNA copies] of COX-2, amphiregulin and tenascin-c normalized to
peptidylprolyl isomerase A (PPIA). COX-2 protein expression by Western Blot analysis. Significant intergroup differences indicated by P values.
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Figure 4 Systemic hematological parameters and inflammatory cytokines. Time courses of systemic TNF-α, IL-6, lactate, leucocytes, and
platelets. *Indicates P < 0.05 vs. baseline value, # P < 0.05 vs. Sepsis/VILI and × P < 0.05 vs. 3 h value. No significant intergroup differences. Sepsis/VILI
values of TNF-α exceed the detection capacities of the available assays.
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Post-mortem macroscopic and histologic evaluations
yielded the presence of a sustained lung injury in both
groups. The AP318 group shows lower scoring values,
but fails to reach significance (Figure 6). The alveolar
protein content was minimal in both groups. The most
pronounced features of the histopathological scoring
were inflammatory infiltration, overdistension, and atel-
ectasis with edema formation playing a minor role. The
CTRL group featured a higher grade of hemorrhage
(Table 3). No relevant differences were detected regard-
ing the ventral to dorsal distribution.Discussion
The key results of the present porcine model of LPS/
VILI-induced lung injury are: (1) AP318 significantly
mitigates pulmonary mRNA expression of inflammatory
mediators despite comparable systemic response to LPS
exposition and (2) gas exchange or histopathological in-
jury did not improve in the presence of low-grade pul-
monary edema within six hours post insult.Model characteristics
LPS is exposed as glycolipids of gram-negative bacteria in
systemic bacteremia and can trigger inflammatory response
to the point of septic shock and cardio-circulatory failure.
Systemic effects of LPS in pigs include hemodynamic de-
terioration along with increased pulmonary arterial pres-
sure and acute leucopenia [22], which is consistent with
our findings. Intrapulmonary changes due to LPS infusion
include accumulation of leucocytes and alveolar macro-
phages, as well as edema formation and endothelial injury
[23]. In contrast to other models (i.e. bronchoalveolar
lavage), no immediate atelectases and gas exchange impair-
ment are generated [23]. In pigs LPS-induced lung changes
measured by computer tomographic imaging and histo-
pathologic scoring can develop over several hours without
fulfillment of ARDS criteria [24]. Endotoxemic shock and
therapy-refractory hemodynamic failure limit the max-
imum possible LPS infusion dosages in experimental
models.
Regarding our primary hypothesis we designed this
model to focus inflammatory response within the lung
and not extensive edema formation or severe gas exchange
Figure 5 Gas exchange and respiratory mechanics. Time courses of
PaO2/FiO2 and Cdyn. *P < 0.05 vs. Baseline. No intergroup differences.
Figure 6 Pathological assessment of the lungs. Global
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our prior studies [12,15]. The present model causes a pul-
monary lesion with a pronounced inflammatory response,
which presents as significant worsening of PaO2/FiO2, re-
spiratory mechanics, and post-mortem lung injury. Never-
theless, the complete pattern of ARDS according to the
current criteria is not achieved despite addition of one-
hour high Vt ventilation. This kind of short-term VILI
does not induce sustained lung injury in healthy pigs [25].
However, synergistic effects of LPS infusion and VILI are
used to achieve a full pattern human-like ARDS in experi-
mental models [22].histopathological respectively macroscopic lung injury scoring and
pulmonary wet to dry ratio. No significant intergroup differences.Influence on inflammatory response
In response to LPS exposure TNF-α and IL-1β are
released into the systemic circulation. In early ARDS al-
veolar macrophages are the main source of inflammatory
Table 2 Ventilation and hemodynamic data
AP318 CTRL
Parameter Baseline Sepsis /VILI 3 h 6 h Baseline Sepsis /VILI 3 h 6 h
Ventilation
Vt (mL kg
−1) 8.8 ± 1.4 25.4 ± 2.0 8.7 ± 0.6 8.7 ± 0.7 8.6 ± 0.9 25.8 ± 0.6 8.5 ± 0.4 8.2 ± 0.6
Pendinsp (cmH2O) 14 ± 2 21 ± 3 21 ± 2 19 ± 4 14 ± 1 21 ± 2 21 ± 3 19 ± 3
RR (min−1) 28 ± 8 9 ± 2 33 ± 7 31 ± 5 33 ± 6 9 ± 1 36 ± 6 33 ± 9
PEEP (cmH2O) 6 ± 1 1 ± 0 5 ± 1 5 ± 1 6 ± 1 1 ± 0 5 ± 0 6 ± 2
FiO2 0.4 1.0 0.4 0.4 0.4 1.0 0.4 0.4
I:E 1:2 1:2 1:2 1:2 1:2 1:2 1:2 1:2
PaCO2 (mmHg) 43 ± 4 35 ± 3 44 ± 5 42 ± 5 45 ± 3 36 ± 5 43 ± 5 42 ± 7
pH 7.41 ± 0.03 7.50 ± 0.08 7.33 ± 0.08 7.34 ± 0.08 7.41 ± 0.04 7.47 ± 0.07 7.34 ± 0.05 7.32 ± 0.08
Hemodynamics
MAP (mmHg) 93 ± 13 103 ± 11 66 ± 13 68 ± 8 99 ± 13 115 ± 12 69 ± 12 62 ± 12
CO (L min−1) 4.6 ± 0.7 4.7 ± 0.7 3.2 ± 0.9 3.9 ± 1.2 4.5 ± 0.5 4.6 ± 0.7 3.2 ± 0.5 3.4 ± 0.7
CVP (mmHg) 12 ± 3 11 ± 2 12 ± 3 13 ± 2 11 ± 3 11 ± 3 13 ± 3 13 ± 3
MPAP (mmHg) 22 ± 3 23 ± 3 33 ± 5 30 ± 8 21 ± 5 26 ± 4 37 ± 8 33 ± 12
NA (μg kg−1 min−1) 0 0 0.8 ± 1.3 2.7 ± 5.0 0 0 0.3 ± 0.5 3.1 ± 5.7
Data are presented as mean ± SD, no relevant intergroup differences. Vt: tidal volume; Pendinsp: end-inspiratory pressure; PEEP: positive end-expiratory pressure;
RR: respiratory rate; FiO2: fraction of inspired oxygen; I:E: inspiration to expiration quotient; PaCO2: arterial partial pressure of carbon dioxide; MAP: mean arterial
pressure; CO: cardiac output; CVP: central venous pressure; MPAP: mean pulmonary arterial pressure; NA: noradrenaline dosage.
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hancing neutrophil accumulation [26,27]. We found high
circulating plasma cytokine levels, which in comparison
to their baselines values showed peaks immediately after
sepsis/VILI induction (TNF-α) or three hours following
induction (IL-6). Pathophysiological relevance is sup-
ported by data demonstrating that early and high circu-
lating levels of IL-6 are associated with increased
mortality [9]. Due to the strict local application of
AP318 and ongoing LPS infusion a systemic effect ap-
pears unlikely, which is supported by our plasma cyto-
kine levels. Interestingly, repetitive AP318 inhalationTable 3 Distribution of histopathological lung injury
summarized in figure 3
non-dependent dependent
Parameter AP318 CTRL AP318 CTRL
Alveolar edema 0 ± 0 0.2 ± 0.6 0 ± 0 0.1 ± 0.2
Interstitial edema 1.0 ± 0.7 1.2 ± 1.1 1.0 ± 0.5 0.9 ± 0.7
Hemorrhage 0.3 ± 0.6 1.3 ± 1.2* 0.5 ± 0.8 1.2 ± 1.1*
Inflammatory infiltration 3.7 ± 0.9 3.5 ± 0.8 3.6 ± 1.0 3.7 ± 0.8
Epithelial destruction 0 ± 0 0.4 ± 0.9 0.1 ± 0.3 0.1 ± 0.2
Microatelectasis 3.6 ± 1.1 3.9 ± 1.2 3.3 ± 1.4 3.4 ± 1.3
Overdistension 3.9 ± 0.8 3.6 ± 1.1 3.5 ± 1.0 3.5 ± 0.9
Data of lung regions (each containing periphery and bronchial area) are
expressed as mean ± SD.
*Indicates P < 0.05 vs. AP318 group.significantly attenuated pulmonary expression of several
key inflammatory markers. Western blot analysis of the
exemplarily chosen marker COX-2 demonstrated a sig-
nificantly reduced content also on the protein level, indi-
cating that the duration of the experiment (6 h) was
sufficient to affect not only transcription, but also and in
parallel direction translation. This observation authenti-
cates the general use of real-time polymerase chain reac-
tion to characterize the effects of AP318 on multiple
markers in the described model.
The TIP peptide’s impact on lung inflammation was
investigated previously in experimental ischemia and re-
perfusion–related lung injury, which demonstrated re-
duced neutrophil accumulation and reactive oxygen
species generation, but failed to show differences in
cytokine levels [11]. In contrast to the present study, the
latter quantified cytokine levels in bronchoalveolar lav-
age fluid, whereas we also determined inflammatory
marker genes directly in lung tissue. Similar to these
data, we found no differences in cytokine levels from the
lavage fluid. Low level of edema formation in our study
may have resulted in a limited effect (Figure 6, Table 3)
on the alveolar cytokine levels. The level of expression is
not dependent on the localization within the lung, which
can be attributed to the systemic character of LPS infu-
sion and the ventilation mode following the one-hour
induction phase. Lung protective ventilation is known to
avoid cyclical recruitment [28], whereas on-going VILI
leads to regional differences in extend of inflammatory
Hartmann et al. BMC Pulmonary Medicine  (2015) 15:7 Page 9 of 11response [24]. The underlying molecular mechanisms of
TIP have not been fully elucidated [11], and the present
study was not design to clarify them. TIP directly acti-
vates ENaC by binding upon the channel’s α-subunit
[29]. In the presence of LPS ENaC expression shows a
biphasic curve with an upregulation within eight hours
followed by a downregulation [30]. ENaC quantification
yielded no significant differences between the two
groups, which assumes that AP318 does not increase
ENaC expression in the present model. Improvement of
gas exchange and reduction of neutrophil invasion by
TIP are linked, as both are inhibited by pharmacological
ENaC blockade [11]. Our data, however, for the first
time demonstrate an attenuation of pulmonary inflam-
matory response without significant edema reduction or
improved gas exchange. Hence, edema absorption itself
is hardly responsible for mitigation of inflammatory
response despite being linked to ENaC. Furthermore,
protein kinase C-α activation, which is induced upon
Ca2+ influx by bacterial cytolysins like pneumolysin or
listeriolysin, is inhibited by TIP [10,31]. This reduces
permeability and reactive oxygen species release. Fur-
ther studies, however, need to clarify, if mitigating of
inflammatory response by a TIP peptide is a primary
mechanism or occurs secondary to the mentioned
mechanisms.
In order to differentiate between LPS and VILI-induced
lung injury, we quantified markers for mechanical and
inflammatory stress in amphiregulin and tenascin-c.
Amphiregulin mRNA levels are induced exclusively
following VILI, but not by LPS administration [25].
Tenascin-c, an extracellular matrix glycoprotein, is par-
ticularly involved in early inflammation and induced by
inflammatory cytokines, lung remodeling, and fibroproli-
feration [32,33]. Tissue amphiregulin levels were not dif-
ferent between AP318 and CTRL group, indicating that
mechanical stress was similar between both groups and
that AP318 did not protect the lung from mechanical
stress. Tenascin-c on the other hand was significantly
lower in the AP318 group, suggesting that AP318 inhal-
ation mitigates the activity associated with inflammation.
Influence on pulmonary function
In the present study gas exchange impairment and respira-
tory mechanics were not improved by AP318 inhalation.
This is in contrast to previous data reporting a rapid
[7,12,15] and lasting [11] amelioration of gas exchange or
respiratory mechanics impairment after TIP peptide inhal-
ation. The failure of compensatory mechanisms may con-
tribute to the low efficacy of AP318 to improve gas
exchange despite mitigation of inflammation: LPS signifi-
cantly impairs pulmonary perfusion and inhibits hypoxic
pulmonary vasoconstriction [34] and LPS-induced lung
injury respond poorly to lung recruitment [35]. Recent datasuggest that lung water content closely correlates with the
ventilation/perfusion-distribution in non-septic experimen-
tal ARDS [36]. Pulmonary edema was not reduced by
AP318, although the main effect of the TIP peptides is
stimulation of ENaC and consequently edema resolution
[9,14]. A porcine ARDS model of bronchoalveolar lavage
and flooding as well as an ex vivo exo-/endotoxin rabbit
model demonstrated that TIP inhalation rapidly resolved a
preformed edema [8,12]. In contrast to these publications
the present model was intentionally not accompanied with
a relevant alveolar edema. Different model characteristics
may therefore account for the lack of efficacy. Hence, the
present data suggest that amelioration of gas exchange by
the lectin-like domain appears to be linked rather to edema
resolution and corresponding lung recruitment than to
anti-inflammatory properties.
Implications and limitations of AP318 inhalation
Three key mechanisms need to be addressed to allow re-
covery from ARDS: resolution of the pulmonary edema,
stabilization of the injured epithelial and endothelial
structures and attenuation of the inflammatory response
[1]. Therapeutic concepts primarily emphasize a strict
adherence to lung protective ventilation and, if applic-
able, treatment of the underlying disease. Experimental
data indicate that TIP peptide inhalation may target at
least two of these pathomechanisms by stimulation of al-
veolar edema reabsorption and reversal of microvascular
hyperpermeability [8,9,12]. The complex pattern of
ARDS requires therapeutic strategies, which address
multiple pathways. TIP peptides are therefore promising
drugs to address endothelial barrier integrity, edema for-
mation and inflammation simultaneously. Via inhalation
the effects are locally restricted making systemic effects
less likely [5,11]. Severe alveolar epithelial injury on the
other hand may also limit beneficial pulmonary effects
[37]. Hence, the lectin-like domain may be better suited
for early states of edematous respiratory failure or ARDS
rather than in severe or late fibroproliferative phases.
Conclusion
In a porcine model of systemic inflammatory response
related lung injury with short-term VILI a repetitive in-
halation of AP318 significantly attenuated the intrapul-
monary expression of inflammatory marker genes. These
findings provide new insights into the mechanisms of
the TNF-α’s lectin-like domain beyond mere edema re-
duction and suggest for the first time an in vivo anti-
inflammatory effect in endotoxemic lung injury.
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